CY1122194T1 - Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανινη και ο τριτοταγης βουτυλεστερας αυτης - Google Patents

Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανινη και ο τριτοταγης βουτυλεστερας αυτης

Info

Publication number
CY1122194T1
CY1122194T1 CY20191101002T CY191101002T CY1122194T1 CY 1122194 T1 CY1122194 T1 CY 1122194T1 CY 20191101002 T CY20191101002 T CY 20191101002T CY 191101002 T CY191101002 T CY 191101002T CY 1122194 T1 CY1122194 T1 CY 1122194T1
Authority
CY
Cyprus
Prior art keywords
oxopyridin
difluorophenyl
ethyl
amino
alanine
Prior art date
Application number
CY20191101002T
Other languages
English (en)
Inventor
Stéphane PINTAT
Stephen John Davies
David Charles Festus Moffat
Original Assignee
Macrophage Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1218640.9A external-priority patent/GB201218640D0/en
Priority claimed from GB201306881A external-priority patent/GB201306881D0/en
Application filed by Macrophage Pharma Limited filed Critical Macrophage Pharma Limited
Publication of CY1122194T1 publication Critical patent/CY1122194T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει έναν μεταβολίτη που παράγεται από την υδρόλυση της εστερικής ένωσης Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2Η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ)-L-αλανινικότερτ-βουτύλιο, ο οποίος είναι χρήσιμος για την αναστολή της δράσης ενός ενζύμου κινάση p38 MAP.
CY20191101002T 2012-10-17 2019-09-23 Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανινη και ο τριτοταγης βουτυλεστερας αυτης CY1122194T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1218640.9A GB201218640D0 (en) 2012-10-17 2012-10-17 Chemical compounds
GB201306881A GB201306881D0 (en) 2013-04-16 2013-04-16 Chemical compounds
PCT/GB2013/052689 WO2014060742A1 (en) 2012-10-17 2013-10-15 Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof
EP13783363.8A EP2909175B1 (en) 2012-10-17 2013-10-15 Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof

Publications (1)

Publication Number Publication Date
CY1122194T1 true CY1122194T1 (el) 2020-11-25

Family

ID=49488610

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100756T CY1119080T1 (el) 2012-10-17 2017-07-17 Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανιnικο tert-boytyλio ή ενα αλας, υδριτης ή διαλυτωμα αυτου
CY20191101002T CY1122194T1 (el) 2012-10-17 2019-09-23 Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανινη και ο τριτοταγης βουτυλεστερας αυτης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100756T CY1119080T1 (el) 2012-10-17 2017-07-17 Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανιnικο tert-boytyλio ή ενα αλας, υδριτης ή διαλυτωμα αυτου

Country Status (27)

Country Link
US (3) US9388136B2 (el)
EP (2) EP2909175B1 (el)
JP (2) JP6260975B2 (el)
KR (1) KR102164536B1 (el)
CN (2) CN106496106B (el)
AU (1) AU2013333636B2 (el)
BR (1) BR112015008167B1 (el)
CA (1) CA2888928C (el)
CY (2) CY1119080T1 (el)
DK (2) DK2909175T3 (el)
ES (2) ES2635240T3 (el)
HK (1) HK1211028A1 (el)
HR (2) HRP20171320T1 (el)
HU (2) HUE046132T2 (el)
IL (2) IL237863B (el)
IN (1) IN2015DN02721A (el)
LT (1) LT3222616T (el)
MX (1) MX364782B (el)
NZ (1) NZ706717A (el)
PL (2) PL3222616T3 (el)
PT (2) PT2909175T (el)
RS (2) RS56184B1 (el)
RU (1) RU2676329C2 (el)
SG (2) SG11201502515VA (el)
SI (2) SI2909175T1 (el)
WO (1) WO2014060742A1 (el)
ZA (1) ZA201501958B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2888928C (en) * 2012-10-17 2020-05-26 Chroma Therapeutics Ltd Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof
GB201713975D0 (en) * 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
ATE375980T1 (de) * 2002-02-12 2007-11-15 Smithkline Beecham Corp Nicotinamide und deren verwendung als p38 inhibitoren
CN1653047A (zh) 2002-03-14 2005-08-10 拜耳医药保健股份公司 抗炎症药物单环芳酰吡啶酮
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
EP1964578A3 (en) 2005-05-05 2008-11-05 Chroma Therapeutics Limited Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
GB0608855D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of MAP kinase enzymes
WO2007129040A1 (en) 2006-05-04 2007-11-15 Chroma Therapeutics Ltd. p38 MAP KINASE INHIBITORS
GB0608837D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of MAP kinase
GB0608823D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of P13 kinase
GB0608821D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd DHFR enzyme inhibitors
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
EA200900593A1 (ru) 2006-10-25 2010-06-30 Хрома Терапьютикс Лтд. Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака
GB0621203D0 (en) 2006-10-25 2006-12-06 Chroma Therapeutics Ltd PLK inhibitors
WO2008053131A1 (en) 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
ATE524454T1 (de) 2006-11-01 2011-09-15 Chroma Therapeutics Ltd Inhibitoren von ikk-beta serinthreoninproteinkinase
NZ576705A (en) 2006-11-01 2011-12-22 Chroma Therapeutics Ltd IKK-Beta SERINE-THREONINE PROTEIN KINASE INHIBITORS
EP2220044A1 (en) 2007-11-07 2010-08-25 Chroma Therapeutics Limited P38 map kinase inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
ES2427892T3 (es) * 2008-02-29 2013-11-04 Chroma Therapeutics Limited Inhibidores de MAP quinasa p38
JP2011518814A (ja) 2008-04-23 2011-06-30 クロマ セラピューティクス リミテッド Ｉｋｋ−ベータセリン−スレオニンプロテインキナーゼの阻害剤
GB0807451D0 (en) 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
EA201001708A1 (ru) 2008-04-26 2011-06-30 Хрома Терапьютикс Лтд. Замещённые тиофенкарбоксамиды их применение в качестве ингибиторов ikk-бета серин-треонин протеинкиназ
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB0907120D0 (en) 2009-04-24 2009-06-03 Chroma Therapeutics Ltd Inhibitors of IKK-ß serine-threonine protein kinase
GB201009853D0 (en) 2010-06-11 2010-07-21 Chroma Therapeutics Ltd HSP90 inhibitors
GB201021467D0 (en) 2010-12-17 2011-02-02 Chroma Therapeutics Ltd Imaging agents
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
CA2888928C (en) * 2012-10-17 2020-05-26 Chroma Therapeutics Ltd Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof

Also Published As

Publication number Publication date
HK1211028A1 (en) 2016-05-13
CA2888928C (en) 2020-05-26
BR112015008167A2 (pt) 2017-07-04
KR102164536B1 (ko) 2020-10-12
JP6464244B2 (ja) 2019-02-06
RS59458B1 (sr) 2019-11-29
BR112015008167B1 (pt) 2020-11-17
PL2909175T3 (pl) 2017-10-31
DK3222616T3 (da) 2019-08-19
ES2635240T3 (es) 2017-10-03
AU2013333636A1 (en) 2015-04-09
SG10201708166SA (en) 2017-11-29
EP2909175A1 (en) 2015-08-26
HRP20171320T1 (hr) 2017-10-20
CY1119080T1 (el) 2018-01-10
CN104781235A (zh) 2015-07-15
US9896417B2 (en) 2018-02-20
MX2015004368A (es) 2015-06-10
RU2015115213A (ru) 2016-12-10
PT3222616T (pt) 2019-09-26
AU2013333636B2 (en) 2017-11-23
NZ706717A (en) 2018-02-23
EP3222616A1 (en) 2017-09-27
SI2909175T1 (sl) 2017-08-31
SG11201502515VA (en) 2015-05-28
MX364782B (es) 2019-05-07
IL237863B (en) 2018-06-28
US9388136B2 (en) 2016-07-12
JP6260975B2 (ja) 2018-01-17
RS56184B1 (sr) 2017-11-30
JP2018048160A (ja) 2018-03-29
RU2676329C2 (ru) 2018-12-28
CN106496106B (zh) 2019-05-10
HUE035525T2 (en) 2018-05-28
SI3222616T1 (sl) 2019-10-30
WO2014060742A1 (en) 2014-04-24
DK2909175T3 (en) 2017-08-14
US10370332B2 (en) 2019-08-06
CN104781235B (zh) 2016-12-21
US20150246883A1 (en) 2015-09-03
IN2015DN02721A (el) 2015-09-04
EP2909175B1 (en) 2017-06-07
IL256560B (en) 2019-07-31
HUE046132T2 (hu) 2020-02-28
JP2015534974A (ja) 2015-12-07
PL3222616T3 (pl) 2019-12-31
ES2743768T3 (es) 2020-02-20
IL256560A (en) 2018-02-28
US20180127371A1 (en) 2018-05-10
EP3222616B1 (en) 2019-07-17
US20160297760A1 (en) 2016-10-13
CN106496106A (zh) 2017-03-15
PT2909175T (pt) 2017-09-13
HRP20191874T1 (hr) 2020-01-10
CA2888928A1 (en) 2014-04-24
ZA201501958B (en) 2016-01-27
LT3222616T (lt) 2019-09-10
KR20150067376A (ko) 2015-06-17

Similar Documents

Publication Publication Date Title
CY1122176T1 (el) Αλατα ενος αναστολεα κινασης υποδοχεα επιδερμικου αυξητικου παραγοντα
CY1120188T1 (el) ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
CY1118212T1 (el) Παραγοντες οι οποιοι τροποποιουν την s1p
DK3034497T3 (da) 3,5-diamino-6-chlor-n-(n-(4-(4-(2-(hexyl(2,3,4,5,6-penta-hydroxyhexyl)amino)ethoxy)phenyl)butyl) carbamimidoyl)pyrazin-2-carboxamid
CY1119489T1 (el) Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
EA201790715A1 (ru) Новые соединения
EA201200741A1 (ru) Способ получения этексилата дабигатрана
NZ715838A (en) Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
NZ724645A (en) Pde10 inhibitors and related compositions and methods
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
UY34442A (es) 2-tiopirimidinonas.
UY34486A (es) Anticuerpos dirigidos al receptor del factor de crecimiento epidérmico 3 (her3) dirigidos contra el dominio ii del her3
EA201591349A1 (ru) Способ получения вортиоксетина
CY1122194T1 (el) Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανινη και ο τριτοταγης βουτυλεστερας αυτης
EA201101152A1 (ru) Лиофилизированный дабигатран
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
ZA201604932B (en) N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
EA201400939A1 (ru) Способ получения медетомидина с использованием хлорацетона
MX2016004393A (es) Derivados de carboxamida como compuestos pesticidas.
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης